Metabolex Names Zhao, Martin to Executive Posts
"These appointments represent a significant development in our company insupport of our expanding research and clinical pipeline," said CharlesMcWherter, Ph.D., Senior Vice President of Research and PreclinicalDevelopment. "Spring brings a winning combination of creativity in medicinalchemistry along with strong credentials in all aspects of drug discovery anddevelopment." Dr. McWherter continued, "Rob is an exceptional asset toMetabolex. He comes with the focus on execution of a biotech but with thesavvy of his formative years in pharmaceutical research. Rob is a real masterof integrating portfolio strategy with practical operational alternatives."
Dr. Zhao joined Metabolex in 2000 as the head of chemistry, and wasinstrumental in building the chemistry department. Over the past eight years,he has served in a variety of operational and leadership roles, most recentlyleading drug discovery projects from lead identification to clinical trials.Earlier in his career, Dr. Zhao worked at Berlex where he contributed to theadvancement of several compounds. Dr. Zhao holds a Ph.D. from the Universityof California Los Angeles, is an inventor on several patents and has publishednumerous scientific papers in the field of drug discovery.
Dr. Martin joined Metabolex in 2004 and has served the company in avariety of preclinical development and project management positions, mostrecently as Senior Director of Portfolio Management. He has played a key rolein a number of projects in the Metabolex pipeline. Prior to joining thecompany, he spent ten years with Roche where in his last position -- in theresearch strategy group -- he focused on improving the productivity of theglobal research organization. Dr. Martin holds a Ph.D. from the University ofCalifornia Davis.
Metabolex is a privately-held biopharmaceutical company focused on thediscovery and development of proprietary new medicines for the treatment ofmetabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawnon its deep understanding of diabetes to create a large database of genesinvolved in diabetes and to build a rich pipeline of product candidates anddrug discovery targets. The company has four clinical-stage compounds:MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044,which has completed a Phase 2a trial; MBX-8025, currently being studied in aPhase 2 trial in patients with dyslipidemia; and MBX-2982, currently beingstudied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right todevelop and commercialize MBX-102/JNJ 39659100. For additional informationabout Metabolex and its development pipeline, visit http://www.metabolex.com.
SOURCE Metabolex, Inc.
You May Also Like